Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients. The precise mechanism of action remains unclear, but preclinical evidence suggests that metformin can sensitize tumor cells to the effects to conventional chemotherapeutic agents and ionizing radiation (IR). In this chapter we describe two assays to investigate the effects of combination of metformin and a chemotherapeutic agent (in this case cisplatin) in head and neck cancer squamous cell carcinoma (HNSCC) cell lines.
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Sang Hyeok
SH
Woo
Vlad C
VC
Sandulache
Liangpeng
L
Yang
Heath D
HD
Skinner
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D006019:Glycolysis / Q000187:drug effects; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D008928:Mitochondria / Q000201:enzymology; D000077195:Squamous Cell Carcinoma of Head and Neck
D000970:Antineoplastic Agents; D008687:Metformin; D002945:Cisplatin